Cytogen to absorb Genome Care in small-scale merger
The Kosdaq-listed firm said the move will integrate reproductive genetics diagnostics with its liquid biopsy business to boost competitiveness.

Cytogen said Wednesday it has decided to merge with its wholly owned subsidiary Genome Care through a small-scale absorption merger. The company plans to integrate Genome Care's reproductive genomics diagnosis business with Cytogen's circulating tumor cell-based precision medicine operations to create synergies.
Under the terms of the merger agreement signed on July 30, Genome Care will cease to exist as a separate legal entity while Cytogen remains the surviving company. The consolidation is scheduled to take effect on Oct. 1 without the issuance of new shares.
The merger is expected to improve operational efficiency by integrating research and development capabilities, inspection operating systems, sales networks and management resources, allowing the company to cut duplicate costs.
Genome Care reported revenue of 11 billion won ($7.67 million) for 2025, up from 8.3 billion won ($5.8 million) in the previous year, while operating profit rose to 2.95 billion won ($2.07 million) from 1.78 billion won ($1.24 million). Net income climbed to 2.69 billion won ($1.88 million) from 1.48 billion won ($1.03 million).
Genome Care specializes in providing prenatal and infertility diagnosis solutions, including non-invasive prenatal tests and pre-implantation genetic tests.
What this article is based on
Every fact in this article can be checked against the primary documents below.
- Regulatory filing싸이토젠 주요사항보고서(회사합병결정)· DART· accessed Aug. 28, 2026
- Regulatory filing액체생검 사업 매출· DART· accessed Aug. 4, 2026
© New Era Korea Daily. All rights reserved.
More in Companies
- Kumho Engineering wins 145 billion won rail contract in North Gyeongsang
- HLB to absorb HLB Life Science in all-stock merger to unify rivoceranib rights
- L&F raises 30.3 billion won in perpetual convertible bonds for cathode expansion
- Meritz Financial third-quarter revenue jumps 78% as net income slips
- Phionx to raise 13.6 billion won via rights issue and convertible bonds